Advances in the treatment of mania

Psychiatric Clinics of North America: Annual of Drug Therapy

Volumn , Issue , 2001, Pages 155-180

  Brambilla, P ^a   Soares, J C ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTICONVULSIVE AGENT; BENZODIAZEPINE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLONAZEPAM; CLOZAPINE; DILTIAZEM; FELBAMATE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LORAZEPAM; MILACEMIDE; NEUROLEPTIC AGENT; NIFEDIPINE; NIMODIPINE; OLANZAPINE; PLACEBO; QUETIAPINE; REMACEMIDE; RISPERIDONE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; VIGABATRIN;

ACUTE DISEASE; AKATHISIA; ALOPECIA; ARTICLE; ASTHENIA; ATAXIA; COGNITIVE DEFECT; CONTROLLED STUDY; DIPLOPIA; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRY EYE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEADACHE; HUMAN; HYPOTHYROIDISM; LIVER FAILURE; MANIA; MONOTHERAPY; NAUSEA; NEUROTOXICITY; PANCREATITIS; POLYURIA; RIGIDITY; SEDATION; SIDE EFFECT; SKIN MANIFESTATION; TACHYCARDIA; TARDIVE DYSKINESIA; THIRST; THROMBOCYTOPENIA; THYROID DISEASE; TREMOR; VERTIGO; VISUAL IMPAIRMENT; WEIGHT GAIN;

EID: 0035200228     PISSN: 10683178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (331)

1. Platelet MAC: Personality and response to lithium prophylaxis
2. Who responds to prophylactic lithium?
3. Flupenthixol decanoate in recurrent manic-depressive illness: A comparison with lithium
4. Gabapentin in the acute treatment of refractory bipolar disorder
5. Lamotrigine treatment of lithium failure outpatient mania: A double blind placebo controlled trial
6. Clozapine treatment of euphoric mania
7. Alprazolam-induced mania: Two clinical cases
8. Verapamil vs lithium in acute mania
9. Clonazepam treatment of five lithium-refractory patients with bipolar disorder
10. The use of lithium in manic depressive psychosis
11. Prophylactic lithium: Double blind discontinuation in manic-depressive and recurrent-depressive disorders
12. Lithium as a prophylactic agent: Its effect against recurrent depressions and manic-depressive psychosis
13. Does lithium treatment still work? Evidence of stable responses over three decades
14. Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders
15. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders
16. Carbamazepine in manic-depressive illness: A new treatment
17. Clozapine therapy in refractory affective disorders: Polarity predicts response in long-term follow-up
18. Response to clozapine in acute mania is more rapid than that of chlorpromazine
19. Valproic acid and immune thrombocytopenia
20. Verapamil in treatment-resistant mania: An open trial
21. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol
22. Carbamazepine vs lithium: Einsatz in der prophylaxe rezidivierender affektiver und schizoaffective psychosen
23. Olanzapine-induced psychotic mania in bipolar schizo-affective disorder
24. Course of illness and pattern of recurrences in patients with affective disorders during long-term lithium prophylaxis: A retrospective analysis over 15 years
25. Lamotrigine and the treatment of mania in bipolar disorder
26. Olanzapine compared to lithium in mania: A double-blind randomized controlled trial
27. Diltiazem-induced psychosis and a possible diltiazem-lithium interaction
28. Valproic-acid-induced pancreatitis: Case report and review of the literature
29. Antiepileptics and blood dyscrasias: A cohort study
30. Thyroid abnormalities during lithium treatment
31. Risperidone: Clinical safety and efficacy in schizophrenia
32. Clonazepam in acute mania: Time-blind evaluation of clinical response and concentrations in plasma
33. The effectiveness of lithium prophylaxis in bipolar and unipolar depressions and schizo-affective disorders
34. Efficacy of divalproex vs lithium and placebo in the treatment of mania: The Depakote Mania Study Group
35. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder: Divalproex Maintenance Study Group
36. Relation of serum valproate concentration to response in mania
37. Double-blind comparison of the effects of clonazepam and lorazepam in acute mania
38. Bipolar affective disorder and substance abuse
39. Verapamil treatment of acute mania
40. A pilot trial of adjunctive topiramate in the treatment of bipolar disorder
41. U.S. experience with valproate in manic depressive illness: A multicenter trial
42. Open trial of a calcium antagonist, nimodipine, in acute mania
43. A comparison of two adjunctive treatment strategies in acute mania
44. Patterns of benzodiazeplne abuse and dependence
45. Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: Results of an open-label study
46. Lithium salts in the treatment of psychotic excitement
47. Treatment of mania using a calcium antagonist: Preliminary trial
48. Treatment of mania by a calcium inhibitor: Preliminary study
49. Clozapine for treatment-refractory mania
50. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients
51. Clozapine prophylaxis in rapid cycling bipolar disorder
52. Predictors of valproate response in bipolar rapid cycling
53. Subclinical lithium neurotoxicity: Correlation of neural conduction abnormalities and serum lithium level in manic-depressive patients with lithium treatment
54. Topiramate as add-on treatment for patients with bipolar mania
55. The use of benzodiazepines in the treatment of manic-depressive illness
56. Clonazepam in acute and maintenance treatment of bipolar affective disorder
57. A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms
58. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
59. New concepts in benzodiazepine therapy: Rebound anxiety and new indications for the more potent benzodiazepines
60. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: A 24-month naturalistic study
61. Use of lithium, carbamazepine, and valproic acid in a state-operated psychiatric hospital
62. Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines
63. 50 years of lithium treatment of mood disorders
64. Prophylactic lithium in affective disorders. Controlled trial
65. Double-blind and open prospective studies on lithium prophylaxis in affective disorders
66. The likelihood of recurrence in bipolar affective disorder: The importance of episode recency
67. Lithium and recurrence in a long-term follow-up of bipolar affective disorder
68. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder
69. A controlled evaluation of lithium prophylaxis in affective disorders
70. De Beaurepaire R. Treatment of neuroleptic-resistant mania and schizoaffective disorders
71. Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder
72. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder
73. Neuroleptic exposure in bipolar outpatients in a research setting
74. Mania associated with risperidone use
75. Valproate hepatotoxicity: A review and report of two instances in adults
76. Does maintenance lithium therapy prevent recurrences of mania under ordinary clinical conditions?
77. The manic syndrome: Factors which may predict a patient's response to lithium, carbamazepine and valproate
78. Depressive mania associated with nonresponse to antimanic agents
79. Tardive dyskinesia in bipolar affective disorder: Relationship to lithium therapy
80. Cortisol, prolactin and growth hormone levels with clinical ratings in manic patients treated with verapamil
81. Use of calcium antagonists in mania
82. Calcium antagonists in manic-depressive illness
83. Increased platelet intracellular calcium concentration in patients with bipolar affective disorders
84. Intracellular calcium ions in affective disorders: A review and an hypothesis
85. Calcium antagonists in mania: A double-blind study of verapamil
86. Effectiveness of verapamil in the treatment of a manic patient
87. Phenelzine-induced hypomania: Effect of verapamil
88. The calcium second messenger system in bipolar disorders: Data supporting new research directions
89. Abnormal intracellular calcium ion concentration in platelets and lymphocytes of bipolar patients
90. Lithium carbonate: Maintenance studies and consequences of withdrawal
91. Lithium carbonate prophylaxis failure
92. Lithium carbonate and affective disorders. V: A double-blind study of prophylaxis of depression in bipolar illness
93. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder
94. Clonazepam in acute mania: A double blind trial
95. Low tolerability of carbamazepine in psychiatric patients may restrict its clinical usefulness
96. Lithium compared to valproic acid and carbamazepine in the treatment of mania: A statistical meta-analysis
97. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders
98. An open label study of gabapentin in the treatment of acute mania
99. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients
100. Episode sequence in bipolar disorder and response to lithium treatment
101. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders
102. The effect of alcohol and substance abuse on the course of bipolar affective disorder
103. Trends in pharmacotherapy of schizoaffective and bipolar affective disorders: A 5-year naturalistic study
104. Lithium therapy at the millenium: A revolutionary drug used for 50 years faces competing options and possible demise
105. Lithium carbonate prophylaxis of depression in three subtypes in primary affective disorder
106. Lithium prophylaxis of depression in bipolar I, bipolar II, and unipolar patients
107. Carbamazepine treatment of selected affectively disordered inpatients
108. Alprazolam-induced manic reaction
109. Uses of clozapine in nonschizophrenic patients
110. Mood stabilizer combinations: A review of safety and efficacy
111. A double-blind comparison of valproate and lithium in the treatment of acute mania
112. Gabapentin and lamotrigine monotherapy in mood disorder
113. A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania
114. Verapamil versus lithium in acute mania
115. A comparison of bipolar patients with and without a borderline personality disorder
116. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder
117. Lithium ion: A specific psychopharmacology approach to the treatment of mania
118. The use of quetiapine for treatment-resistant bipolar disorder: A case series
119. Long-term risperidone treatment in bipolar disorder: 6-month follow-up
120. Acute treatment of bipolar disorder with adjunctive risperidone in outpatients
121. Antimanic effects of verapamil
122. Comparison of antimanic efficacy of clonidine and verapamil
123. Comparison of lithium carbonate, valproic acid and verapamil in the treatment of manic symptoms
124. The safety of olanzapine compared with other antipsychotic drugs: Results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia
125. A case of alprazolam, but not lorazepam, inducing manic symptoms
126. Verapamil prophylaxis in pregnant women with bipolar disorder
127. Treatment of mania: Relationship between response to verapamil and changes in plasma calcium and magnesium levels
128. Nimodipine treatment of rapid cycling bipolar disorder
129. Anticonvulsant therapy and suicide risk in affective disorders
130. The impact of mood stabilizers on suicide in bipolar disorder: A comparative analysis
131. Lithium-carbonate treatment in depression and mania. A longitudinal double-blind study
132. Lithium in the treatment of mania: Comparisons with neuroleptics
133. Recurrence of mania after lithium withdrawal: Implications for the use of lithium in the treatment of bipolar affective disorder
134. Mood stabilization and weight loss with topiramate
135. Treatment of manic episodes: Zuclopenthixol and clonazepam versus lithium and clonazepam
136. Clozapine in the treatment of refractory psychotic mania
137. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder
138. Carbamazepine vs chlorpromazine in mania: A double blind trial
139. Intravenous valproate loading in acutely manic and depressed bipolar I patients
140. Combined treatment with lithium and nimodipine in a bipolar I manic syndrome
141. Il citrato di litio nel trattamento degli stati di eccitazione psicotica
142. Clinical experience with valproic acid in 22 patients with refractory bipolar mood disorder [letter]
143. Lithium prophylaxis in recurrent affective illness: Efficacy, effectiveness and efficiency
144. Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder
145. Gabapentin in the treatment of bipolar disorders
146. Outcome in manic disorders: A naturalistic follow-up study
147. The use of lithium salts in affective disorders
148. Incidence and significance of mixed affective states in a bipolar population
149. Age, dementia, dyskinesias, and lithium response
150. Verapamil in affective disorders: A controlled, double-blind study
151. Prophylactic lithium in recurrent affective disorders
152. Tardive dyskinesia in bipolar affective disorder: A catchment area study
153. Valproate, hyperandrogenism, and polycystic ovaries: A report of 3 cases
154. Low-dose valproate: A new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome
155. Suicide and bipolar disorder
156. Advances in the treatment of mania and related disorders: A reappraisal
157. Verapamil for the treatment of acute mania: A double-blind, placebo-controlled trial
158. Carbamazepine for patients with affective target symptoms
159. Comparative effects of lithium and chlorpromazine in the treatment of acute manic states
160. Controlled evaluation of lithium and chlorpromazine in the treatment of manic states: An interim report
161. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
162. Tardive dyskinesia in affective disorders
163. Verapamil and valproic acid treatment of prolonged mania
164. Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder
165. Valproate oral loading in the treatment of acute mania
166. Bipolar I: A five-year prospective follow-up
167. Refractory bipolar illness may not respond to verapamil
168. Human liver carbamazepine metabolism: Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation
169. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey
170. Metabolism and excretion of mood stabilizers and new anticonvulsants
171. Treatment of bipolar I disorder in an adolescent with olanzapine
172. Clozapine in treatment-refractory mood disorders
173. The lithium treatment of hypomanic and manic states
174. Clinical experience using gabapentin adjunctively in patients with a history of mania or hypomania
175. Topiramate augmentation in women with refractory rapid cycling bipolar disorder and significant weight gain from previous treatment
176. Adolescent bipolar illness and personality disorder
177. Adjunctive treatment of manic agitation with lorazepam versus haloperidol: A double-blind study
178. Use of carbamazepine in acute psychosis: A controlled study
179. Effectiveness of the combination verapamil and chlorpromazine in the treatment of severe manic or mixed patients
180. Carbamazepine versus lithium in mania: A double-blind study
181. Psychotropic drug prescription patterns among patients with bipolar I disorder
182. Calcium channel antagonists for the treatment of bipolar disorder
183. Clozapine: Guidelines for clinical management
184. Flunarizine as maintenance treatment of a patient with bipolar disorder
185. Olanzapine-induced manic-like syndrome
186. Depot antipsychotics in the prophylaxis of bipolar affective disorder
187. Carbamazepine vs lithium in the treatment and prophylaxis of mania
188. Treatment of manic illness with lithium carbonate
189. Clozapine in the management of bipolar and schizoaffective manic episodes resistant to standard treatment
190. The impact of lithium prophylaxis on the course of bipolar disorder: A review of the research evidence
191. Lithium prophylaxis of schizoaffective disorders: A prospective study
192. Effectiveness of lithium prophylaxis in schizoaffective psychoses: Application of a polydiagnostic approach
193. Long-term impact of lithium prophylaxis on the course of bipolar disorder
194. Long-term outcome of lithium prophylaxis in bipolar patients
195. Late non-response to lithium prophylaxis in bipolar patients: Prevalence and predictors
196. Long-term outcome of lithium prophylaxis in bipolar disorder: A 5-year prospective study of 402 patients at a lithium clinic
197. Rapid recurrence of mania following abrupt discontinuation of lithium
198. Pathologic assessment of cerebellar atrophy following acute lithium intoxication
199. Efficacy of lithium prophylaxis in clinical practice
200. Efficacy of verapamil in mania crises
201. Alprazolam-induced manic reaction
202. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia
203. Olanzapine in treatment-resistant bipolar disorder
204. Sodium valproate: Its use in primary psychiatric disorders
205. Valproate in the treatment of rapid-cycling bipolar disorder
206. Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania
207. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania
208. A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder
209. Open-label adjunctive topiramate in the treatment of bipolar disorders
210. Prophylactic lithium: A double-blind trial in recurrent affective disorders
211. Withdrawal syndrome with gradual tapering of alprazolam
212. Inpatient clinical trial of lorazepam for the management of manic agitation
213. Lithium revisited: A re-examination of the placebo-controlled trials of lithium prophylaxis in manic-depressive disorder
214. Persistent tardive dyskinesia in bipolar patients
215. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: A prospective, randomized, double-blind, placebo-controlled, multicenter study
216. Observations on the use of lithium carbonate in psychiatry
217. Lithium treatment of maniacal psychosis
218. Outcome of bipolar disorder on long-term treatment with lithium
219. Re: Hypomania associated with risperidone
220. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: A double-blind controlled study
221. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness
222. Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis: A preliminary report
223. Clinical efficacy of carbamazepine in affective, schizoaffective, and schizophrenic disorders
224. Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study
225. Clonazepam treatment of atypical bipolar disorder
226. Combination treatment in bipolar disorder
227. Treatment of acute mania with verapamil
228. Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness
229. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation
230. Alprazolam-induced manic episode in two patients with panic disorder
231. Carbamazepine side effects in children and adults
232. Parkinsonian symptoms with lithium, lithium-neuroleptic, and lithium-antidepressant treatment
233. Tardive dyskinesia in patients receiving lithium maintenance therapy
234. Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states
235. Lithium prophylaxis of bipolar illness: The value of combination treatment
236. A nifedipine-induced inhibition of lithium clearance
237. The comparative efficacy and safety of carbamazepine versus lithium: A randomized, double-blind 3-year trial in 83 patients
238. A comparison of lithium carbonate and chlorpromazine in mania
239. Le traitment des etats maniaques par les sels de lithium
240. Valproate in the treatment of acute mania: A placebo-controlled study
241. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder
242. Carbamazepine and its -10,11-epoxide metabolite in plasma and CSF: Relationship to antidepressant response
243. Correlates of antimanic response to carbamazepine
244. Lithium in the treatment of mood disorders
245. Neurotoxicity caused by lithium-verapamil synergism
246. Prophylactic efficacy of lithium carbonate in manic-depressive illness
247. Comparison of lithium carbonate and chlorpromazine in the treatment of mania
248. Factors associated with treatment success in lithium carbonate prophylaxis
249. Treatment of mixed mania
250. Lithium carbonate and imipramine in prevention of affective episodes: A comparison in recurrent affective illness
251. NIMH workshop report on treatment of bipolar disorder
252. Valproic acid amide in the treatment of affective and schizoaffective disorders
253. Alprazolam-induced hypomania
254. Olanzapine-induced mania
255. Comorbidity of mental disorders with alcohol and other drug abuse
256. The NIMH Epidemiologic Catchment Area program: Historical context, major objectives, and study population characteristics
257. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy
258. Use of clonazepam for bipolar affective disorder
259. Clonazepam vs. neuroleptics as adjuncts to lithium maintenance
260. Risperidone therapy in treatment refractory acute bipolar and schizoaffective mania
261. Gabapentin in the treatment of bipolar disorder
262. The use of risperidone in the treatment of bipolar disorder
263. The use of lithium carbonate in the treatment of manic psychoses
264. Perspectives on lithium treatment of bipolar disorder: Action, efficacy, effect on suicidal behavior
265. The treatment of manic psychoses by the administration of lithium salts
266. Mania: Diagnosis, state measurement and prediction of treatment response
267. Risperidone compared with both lithium and haloperidol in mania: A double-blind randomized controlled trial
268. Chronic neuroleptic exposure in bipolar outpatients
269. Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic
270. Carbamazepine in affective disorders
271. Response to maintenance therapy in bipolar illness: Effect of index episode
272. Treatment of rapid cycling bipolar disorder with combination therapy of valproate and lithium
273. Psychoactive drugs in mania: A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol
274. Treatment of elderly institutionalized bipolar patients with clozapine
275. The comparative efficacy of carbamazepine low and high serum level and lithium carbonate in the prophylaxis of affective disorders
276. Lithium combined with carbamazepine or haloperidol in the treatment of mania
277. Carbamazepine compared with lithium in the treatment of mania
278. Valproate treatment and the risk of hyperandrogenism and polycystic ovaries
279. Adjunctive antipsychotic use in bipolar patients: An open 6-month prospective study following an acute episode
280. The lithium ion: A foundation for psychopharmacological specificity
281. Gabapentin as an adjunct to standard mood stabilizers in outpatients with mixed bipolar symptomatology
282. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder
283. Olanzapine in the treatment of adolescent acute mania: A report of seven cases
284. A double-blind comparison of lithium and chlorpromazine in the treatment of manic states
285. The use of lithium in affective disorders. 3. A double-blind study of prophylaxis in bipolar illness
286. Efficacy of lithium as acute treatment of manic-depressive illness
287. Neurologic factors predict a favorable valproate response in bipolar and schizoaffective disorders
288. Carbamazepine versus haloperidol in manic syndrome: First report of a multicentric study in Germany
289. Three case reports of acute paroxysmal excitement associated with alprazolam treatment
290. The effects of antecedent substance abuse on the development of first-episode psychotic mania
291. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder
292. Discontinuation of maintenance treatment in bipolar disorder: Risks and implications
293. Clozapine in the treatment of dysphoric mania
294. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania
295. Mania: Differential effects of previous depressive and manic episodes on response to treatment
296. Depression during mania: Treatment response to lithium or divalproex
297. Lithium treatment of mania: Clinical characteristics, specificity of symptom change, and outcome
298. Comparison of efficacy of lithium carbonate and chlorpromazine in mania
299. Etude de l'action des sels de lithium aux etats d'excitation psychomotrice
300. Olanzapine versus placebo in the treatment of acute mania
301. Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study
302. Prediction of outcome in mania by mood-congruent or mood-incongruent psychotic features
303. Outcome in mania: A 4-year prospective follow-up of 75 patients utilizing survival analysis
304. Four-year follow-up of twenty-four first-episode manic patients
305. Risperidone in the treatment of mania
306. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol
307. Rispiridone and mania
308. Reduced suicide risk during lithium maintenance treatment
309. Lithium and suicide risk in bipolar disorder
310. Alcohol problems and long-term psychosocial outcome in Chinese patients with bipolar disorder
311. The high affinity inositol transport system-implications for the pathophysiology and treatment of bipolar disorder
312. Topiramate in severe treatment refractory mania
313. A survey of prescribing practice of antipsychotic maintenance treatment for manic-depressive outpatients
314. Outcome of lithium prophylaxis: A prospective follow-up of affective disorder patients assigned to high and low serum lithium levels
315. Problemy Psichiatrie y Praxi a ve Vyskumu
316. Tardive dyskinesia in bipolar affective disorder: Aging, cognitive dysfunction, course of illness, and exposure to neuroleptics and lithium
317. Superiority of lithium over verapamil in mania: A randomized, controlled, single-blind trial
318. The effect of carbamazepine and lithium on remission from affective illness
319. Adjunctive use of olanzapine in mood disorders: Five case reports
320. Cross-national epidemiology of major depression and bipolar disorder
321. The use of lithium in the affective psychoses
322. Depot antipsychotics in bipolar affective disorder
323. Manic Depressive Illness
324. Tardive dyskinesia and the primary psychiatric diagnosis
325. Predictors of lithium prophylaxis in bipolar patients
326. Clinical predictors of acute response with olanzapine in psychotic mood disorders
327. Clinical predictors of acute response with quetiapine in psychotic mood disorders
328. Clozapine in severe mood disorders
329. Is clozapine a mood stabilizer?